Otrivin Menthol (Xylometazoline Hydrochloride)

Xylometazoline hydrochloride, the active ingredient in Otrivin Menthol, is an Alpha‑2‑adrenergic agonist presented as a nasal spray for topical intranasal use. It relieves nasal congestion associated with colds, sinusitis and allergic rhinitis in adults and children. GNH USA supplies Otrivin Menthol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Otrivin Menthol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otrivin Menthol (xylometazoline hydrochloride) acts on the nasal mucosa to reduce swelling and improve airflow.

- Common cold: temporary relief of nasal congestion. - Acute sinusitis: reduction of nasal passage obstruction. - Allergic rhinitis: alleviation of congestion caused by seasonal allergens. - Upper respiratory tract infection: improves breathing comfort during infection.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nasal burning or stinging sensation. - Mild headache. - Dryness of the nasal mucosa. - Sneezing. - Unpleasant taste.

Serious or Rare Side Effects: - Persistent nasal irritation or ulceration. - Rebound congestion after prolonged use (>5‑d). - Severe headache or facial pain. - Nasal bleeding (epistaxis). - Allergic reaction such as rash, itching or swelling.

Use Otrivin Menthol only when indicated and follow professional guidance.

- Age restriction: not recommended for children under 6 years without medical advice. - Duration limit: limit use to 3‑5 days to avoid rebound congestion. - Pre‑existing conditions: consult if you have hypertension, heart disease or thyroid disorders. - Concomitant nasal sprays: avoid using other decongestant sprays simultaneously. - Pregnancy & lactation: discuss with your health‑care provider. - Store at room temperature: keep in the original packaging, protect from moisture and direct light.

The nasal spray ​​​​      ...  ...